Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Creo Medical reports year of solid progress
(Sharecast News) - Surgical endoscopy medical device specialist Creo Medical Group reported solid progress over the last 12 months in an update on Wednesday, as it leveraged funds from the March 2023 equity raise to advance its strategic goals.
The AIM-traded firm, which was holding its annual general meeting, said achievements included the accelerated launch of the Speedboat UltraSlim device in the EU, now also being used in the US, the Asia-Pacific region, and Latin America, receiving positive feedback from clinicians.
It also noted that the Pioneer training programme saw a 119% increase in worldwide users in 2023.
Recent NHS Supply Chain data validated the effectiveness of Creo's technology, reporting net cash savings of £687,000 from 130 Speedboat procedures at one NHS Trust.
Additionally, Creo received the King's Award for Enterprise in Innovation, recognising its innovative technology platform.
Creo said its Kamaptive partnerships had also showcased the potential of its technology, with the MicroBlate Flex being used in a world-first combined procedure at the Royal Brompton Hospital to treat a cancerous lung nodule using a robotic platform.
Despite the business growth, Creo said it had maintained disciplined cost control, contributing to a reduced operating loss for the financial year ended 31 December 2023.
The company said it remained on track to achieve cash flow break-even by 2025.
"The transition from a small medtech start-up, to where the company is now, is testament to not only the quality of the company's technology and products, but also to its leadership, of which you have been an integral part," the incoming chair Kevin Crofton told the meeting.
"With a strong international presence, a growing user base and world-class partners, Creo Medical is now well positioned for accelerated growth.
"During my recruitment process, I have got to know many members of the talented Creo team, and I am looking forward to getting started and working with them to continue our upwards clinical and commercial trajectory."
At 1256 BST, shares in Creo Medical Group were up 0.33% at 32.35p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.